Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
BACKGROUND
Hyperuricemia and posttransplantation erythrocytosis (PTE) are frequent complications after kidney transplantation and are important risk factors for cardiovascular events. Losartan decreases serum uric acid and hemoglobin (Hb) concentrations and may be a useful agent for treatment of hyperuricemia and PTE.


OBJECTIVE
To evaluate the influence of losartan on serum creatinine (SCr), serum uric acid, and hemoglobin (Hb) concentrations in patients after kidney transplantation and to evaluate the safety profile of losartan in these patients.


METHODS
Sixty-six Han Chinese patients (43 men and 23 women; mean [SD] age, 40.45 [11.50] years) were enrolled in the study. All patients had undergone a first cadaveric donor kidney transplantation at least 3 months previously and had stable graft function with SCr concentration less than 176.8 micromol/L and Hb concentration greater than 110 g/L. The patients were divided into 2 groups (losartan group, n = 34; and control group, n = 32) according to the odevity of patient identification number. Patients in the losartan group received losartan, 50 mg/d; patients in the control group did not receive losartan. Each patient was followed up for 6 months.


RESULTS
Nine patients in the losartan group and 5 patients in the control group dropped out because of acute renal insufficiency, anemia, acute rejection, or poor compliance. The serum uric acid concentration in the losartan group continuously decreased at months 1, 2, 3, and 6 (P = .12, P = .01, P = .04, and P = .005 compared with baseline, and P = .02, P = .003, P = .02, and P = .006 compared with control), especially in the patients with hyperuricemia (P = .02, P < .001, P = .003, and P < .001 compared with baseline, and P = .02, P = .002, P = .02, and P = .002 compared with control). The Hb level in the losartan group decreased significantly at months 1, 2, 3, and 6 (P = .003, P < .001, P = .004, and P = 0.02 compared with baseline, and P = .001, P < .001, P = .001, and P = .005 compared with control), especially in patients with PTE. In patients without PTE, there was no significant decline in Hb concentration in the losartan group compared with baseline. There was no significant decline in estimated glomerular filtration rate in the losartan group.


CONCLUSIONS
Losartan may be an effective agent for treatment of hyperuricemia and PTE in Han Chinese patients after kidney transplantation. However, in some patients, losartan may not be safe.
Zhu
X
X
Center for Renal Transplantation, Jiulisong Hospital, Zhejiang, China.
Chen
J
J
Han
F
F
Cheng
M
M
Xu
L
L
Zhang
L
L
Ding
X
X
Le
Y
Y
D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D047228:Angiotensin II Type 1 Receptor Blockers; D001794:Blood Pressure; D016022:Case-Control Studies; D016572:Cyclosporine / Q000097:blood; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011086:Polycythemia / Q000188:drug therapy* / Q000209:etiology; D011446:Prospective Studies; D044140:Receptor, Angiotensin, Type 1 / Q000819:agonists; D012449:Safety; D014527:Uric Acid / Q000097:blood
D047228:Angiotensin II Type 1 Receptor Blockers; D007166:Immunosuppressive Agents; D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II; D014527:Uric Acid; D016572:Cyclosporine; D019808:Losartan